GNCA Insider Trading Activity and SEC Form 4 Filings
GNCA insider trading summary
No open-market insider purchases or sales of Genocea Biosciences, Inc. (GNCA) have been reported on SEC Form 4 in the past 12 months.
Latest GNCA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 2, 2022 | William D Clark | President and CEO | Sell | $241 (4,023 @ $0.06) |
| Jun 2, 2022 | Jessica Baker Flechtner | Chief Scientific Officer | Sell | $95 (1,578 @ $0.06) |
| Jun 2, 2022 | Diantha Duvall | Chief Financial Officer | Sell | $81 (1,355 @ $0.06) |
| Jun 1, 2022 | Jacquelyn L Sumer | Chief Legal & Compliance Off | Sell | $150 (2,500 @ $0.06) |
| May 31, 2022 | William D Clark | President and CEO | Sell | $7K (117,244 @ $0.06) |
| May 27, 2022 | George Siber | Director | Sell | $1K (20,425 @ $0.07) |
| May 26, 2022 | Diantha Duvall | Chief Financial Officer | Sell | $2K (24,407 @ $0.08) |
| May 25, 2022 | Forest Baskett | 10% Owner | Sell | $363K (4,445,093 @ $0.08) |
| May 25, 2022 | Raymond D Stapleton Jr | Chief Technology Officer | Sell | $223 (2,500 @ $0.09) |
| May 25, 2022 | Scott D Sandell | 10% Owner | Sell | $363K (4,445,093 @ $0.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.